CAPR · As filed with the SEC
Capricor Therapeutics income statement, by fiscal year
The statement as Capricor Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Revenue | 0 | — | — | — | — | — | — | — |
| TOTAL REVENUE | 0 | 22,270,465 | 25,178,066 | 2,551,469 | 244,898 | 310,250 | 1,005,028 | 1,671,356 |
| OPERATING EXPENSES | ||||||||
| Research and development | 84,454,595 | 49,968,585 | 36,448,039 | 21,816,949 | 13,571,045 | 8,457,000 | 5,141,805 | 12,066,800 |
| General and administrative | 23,687,535 | 14,866,722 | 12,807,886 | 10,431,903 | 7,612,295 | 5,543,221 | 3,597,111 | 4,931,642 |
| TOTAL OPERATING EXPENSES | 108,142,130 | 64,835,307 | 49,255,925 | 32,248,852 | 21,183,340 | 14,000,221 | 8,738,916 | 16,998,442 |
| LOSS FROM OPERATIONS | (108,142,130) | (42,564,842) | (24,077,859) | (29,697,383) | (20,938,442) | (13,689,971) | (7,733,888) | (15,327,086) |
| OTHER INCOME (EXPENSE) | ||||||||
| Other income | 45,421 | 7,471 | 67,657 | 190,582 | 548,207 | — | — | — |
| Investment income | 6,257,607 | 2,202,990 | 1,728,701 | 521,535 | 57,460 | 32,943 | 94,791 | 135,991 |
| Interest expense | — | — | — | — | — | — | — | 0 |
| Forgiveness of loan payable | — | — | — | — | — | — | — | 0 |
| Forgiveness of debt | — | — | — | 0 | 318,160 | — | — | — |
| Interest expense | (3,045,725) | — | — | — | — | — | — | — |
| Loss on disposal of fixed assets | (157,519) | (112,805) | (6,041) | (34,266) | (7,905) | 0 | (2,720) | — |
| TOTAL OTHER INCOME (EXPENSE) | 3,099,784 | 2,097,656 | 1,790,317 | 677,851 | 915,922 | 32,943 | 92,071 | 135,991 |
| LOSS BEFORE INCOME TAXES | (105,042,346) | — | — | — | — | — | — | — |
| (Provision for) benefit from income taxes | (1,600) | — | — | — | — | — | — | — |
| NET LOSS | (105,043,946) | (40,467,186) | (22,287,542) | (29,019,532) | (20,022,520) | (13,657,028) | (7,641,817) | (15,191,095) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||||||||
| Net unrealized gain (loss) on marketable securities | (743,801) | 791,142 | 130,569 | 105,244 | 0 | 757 | (13,150) | 773 |
| COMPREHENSIVE LOSS | (105,787,747) | (39,676,044) | (22,156,973) | (28,914,288) | (20,022,520) | (13,656,271) | (7,654,967) | (15,190,322) |
| Net loss per share, basic and diluted | — | — | — | — | — | (0.88) | (2.06) | (0.52) |
| Weighted average number of shares, basic and diluted | — | — | — | — | — | 15,571,056 | 3,711,333 | 29,410,973 |
| Net loss per share, basic (in dollars per share) | (2.26) | (1.15) | (0.83) | (1.18) | (0.87) | — | — | — |
| Net loss per share, diluted (in dollars per share) | (2.26) | (1.15) | (0.83) | (1.18) | (0.87) | — | — | (0.52) |
| Weighted average number of shares, basic (in shares) | 46,478,416 | 35,218,628 | 26,778,360 | 24,552,688 | 23,089,323 | — | — | — |
| Weighted average number of shares, diluted (in shares) | 46,478,416 | 35,218,628 | 26,778,360 | 24,552,688 | 23,089,323 | — | — | 29,410,973 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.